Hubei Qianjiang Pharmaceutical Co., Ltd (hereinafter referred to as "Qianjiang Pharmaceuticals"), located in the hometown of crayfish, China's star city - Qianjiang, its headquarters in the Qianjiang Pharmaceutical Biomedical Industrial Park, covers an area of 140,000 square meters. The company was founded in the 1970s, after more than 40 years of unremitting efforts, has developed into a comprehensive production, learning, research in one of the integrated Chinese and Western pharmaceutical enterprises, and under the jurisdiction of the production of APIs subsidiary - Hubei Jianqi Pharmaceutical Co. The company has first-class production equipment, advanced production technology, strong scientific research strength, excellent marketing team and high-quality staff, and has established a complete modern enterprise management system and processes.
Qianjiang Pharmaceutical, as a high-tech enterprise supported by the state and a national ophthalmic drug production base, insists on R&D as a guide, continues to invest in R&D, establishes close contact and cooperation with domestic and foreign R&D organizations, and in October 2012, signed an agreement with the U.S. TNI Corporation to **** the same R&D of anticancer drugs, and actively integrates into the international market. The company now has 15 major dosage form production lines and 123 product specifications, including lyophilizers and eye drops, which have passed the national GMP certification as a whole; it has an annual production capacity of 80 million lyophilizers, 200 million small-volume injections, 200 million solid preparations and 200 million eye drops.
The company adheres to the ophthalmic drugs as the main feature, lyophilized agents, APIs as the main direction, and is committed to steadily advancing the development of traditional pharmaceutical preparations, to build the production base of ophthalmic drugs and antiviral, anti-infective drug production bases, and at the same time focusing on the development of high-precision new anti-tumor drugs, biomedicine and traditional Chinese medicine products, to enhance the core competitiveness of the company's competitiveness and profitability.